Large-Scale Production of CD4+ T Cells from HIV-1-Infected Donors After CD3/CD28 Costimulation*

1998 ◽  
Vol 7 (5) ◽  
pp. 437-448 ◽  
Author(s):  
BRUCE L. LEVINE ◽  
JULIO COTTE ◽  
CAROLYNN C. SMALL ◽  
RICHARD G. CARROLL ◽  
JAMES L. RILEY ◽  
...  
Marine Drugs ◽  
2021 ◽  
Vol 19 (5) ◽  
pp. 241
Author(s):  
Shaden A. M. Khalifa ◽  
Eslam S. Shedid ◽  
Essa M. Saied ◽  
Amir Reza Jassbi ◽  
Fatemeh H. Jamebozorgi ◽  
...  

Cyanobacteria are photosynthetic prokaryotic organisms which represent a significant source of novel, bioactive, secondary metabolites, and they are also considered an abundant source of bioactive compounds/drugs, such as dolastatin, cryptophycin 1, curacin toyocamycin, phytoalexin, cyanovirin-N and phycocyanin. Some of these compounds have displayed promising results in successful Phase I, II, III and IV clinical trials. Additionally, the cyanobacterial compounds applied to medical research have demonstrated an exciting future with great potential to be developed into new medicines. Most of these compounds have exhibited strong pharmacological activities, including neurotoxicity, cytotoxicity and antiviral activity against HCMV, HSV-1, HHV-6 and HIV-1, so these metabolites could be promising candidates for COVID-19 treatment. Therefore, the effective large-scale production of natural marine products through synthesis is important for resolving the existing issues associated with chemical isolation, including small yields, and may be necessary to better investigate their biological activities. Herein, we highlight the total synthesized and stereochemical determinations of the cyanobacterial bioactive compounds. Furthermore, this review primarily focuses on the biotechnological applications of cyanobacteria, including applications as cosmetics, food supplements, and the nanobiotechnological applications of cyanobacterial bioactive compounds in potential medicinal applications for various human diseases are discussed.


Vaccine ◽  
1989 ◽  
Vol 7 (2) ◽  
pp. 189
Author(s):  
N. Barrett ◽  
A. Mitterer ◽  
J. Eibl ◽  
M. Eibl ◽  
B. Moss ◽  
...  

1989 ◽  
Vol 5 (2) ◽  
pp. 159-171 ◽  
Author(s):  
NOEL BARRETT ◽  
ARTUR MITTERER ◽  
WOLFGANG MUNDT ◽  
JOHANN EIBL ◽  
MARTHA EIBL ◽  
...  

2009 ◽  
Vol 7 (3) ◽  
pp. 339-353 ◽  
Author(s):  
Claudia Jursik ◽  
Michaela Prchal ◽  
Regina Grillari-Voglauer ◽  
Karel Drbal ◽  
Elke Fuertbauer ◽  
...  

Pharmaceutics ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 1669
Author(s):  
Shalom D. Goldberg ◽  
Nathan Felix ◽  
Michael McCauley ◽  
Ryan Eberwine ◽  
Lou Casta ◽  
...  

Autoimmune diseases such as rheumatoid arthritis are caused by immune system recognition of self-proteins and subsequent production of effector T cells that recognize and attack healthy tissue. Therapies for these diseases typically utilize broad immune suppression, which can be effective, but which also come with an elevated risk of susceptibility to infection and cancer. T cell recognition of antigens is driven by binding of T cell receptors to peptides displayed on major histocompatibility complex proteins (MHCs) on the cell surface of antigen-presenting cells. Technology for recombinant production of the extracellular domains of MHC proteins and loading with peptides to produce pMHCs has provided reagents for detection of T cell populations, and with the potential for therapeutic intervention. However, production of pMHCs in large quantities remains a challenge and a translational path needs to be established. Here, we demonstrate a fusion protein strategy enabling large-scale production of pMHCs. A peptide corresponding to amino acids 259–273 of collagen II was fused to the N-terminus of the MHC_II beta chain, and the alpha and beta chains were each fused to human IgG4 Fc domains and co-expressed. A tag was incorporated to enable site-specific conjugation. The cytotoxic drug payload, MMAF, was conjugated to the pMHC and potent, peptide-specific killing of T cells that recognize the collagen pMHC was demonstrated with tetramerized pMHC-MMAF conjugates. Finally, these pMHCs were incorporated into MMAF-loaded 3DNA nanomaterials in order to provide a biocompatible platform. Loading and pMHC density were optimized, and peptide-specific T cell killing was demonstrated. These experiments highlight the potential of a pMHC fusion protein-targeted, drug-loaded nanomaterial approach for selective delivery of therapeutics to disease-relevant T cells and new treatment options for autoimmune disease.


Author(s):  
C. Ferreras ◽  
B. Pascual-Miguel ◽  
C. Mestre-Durán ◽  
A. Navarro-Zapata ◽  
L. Clares-Villa ◽  
...  

Syndrome coronavirus 2 (SARS-CoV-2) pandemic is causing a second outbreak significantly delaying the hope for the virus’ complete eradication. In the absence of effective vaccines, we need effective treatments with low adverse effects that can treat hospitalized patients with COVID-19 disease. In this study, we determined the existence of SARS-CoV-2-specific T cells within CD45RA– memory T cells in the blood of convalescent donors. Memory T cells can respond quickly to infection and provide long-term immune protection to reduce the severity of COVID-19 symptoms. Also, CD45RA– memory T cells confer protection from other pathogens encountered by the donors throughout their life. It is of vital importance to resolve other secondary infections that usually develop in patients hospitalized with COVID-19. We found SARS-CoV-2-specific memory T cells in all of the CD45RA– subsets (CD3+, CD4+, and CD8+) and in the central memory and effector memory subpopulations. The procedure for obtaining these cells is feasible, easy to implement for small-scale manufacture, quick and cost-effective, involves minimal manipulation, and has no GMP requirements. This biobank of specific SARS-CoV-2 memory T cells would be immediately available “off-the-shelf” to treat moderate/severe cases of COVID-19, thereby increasing the therapeutic options available for these patients.


1995 ◽  
Vol 6 (4) ◽  
pp. 512-518 ◽  
Author(s):  
M.E. Gustafson ◽  
K.D. Junger ◽  
B.A. Foy ◽  
J.A. Baez ◽  
B.F. Bishop ◽  
...  

2020 ◽  
Author(s):  
C Ferreras ◽  
B Pascual-Miguel ◽  
C Mestre-Durán ◽  
A Navarro-Zapata ◽  
L Clares-Villa ◽  
...  

ABSTRACTSARS-CoV-2 is causing a second outbreak so the hope for its complete eradication is far from happening. In the absence of effective vaccines, it is mandatory to find effective treatments with low adverse effects able to treat hospitalized patients with COVID-19 disease. In this work, we determined the existence of SARS-CoV-2 specific T cells within the CD45RA− T memory cells from the blood of convalescent donors. Memory T cells can respond quickly to the infection and provide long-term immune protection to reduce the severity of the COVID-19 symptoms. Also, CD45RA− memory T cells confer protection from other pathogens the donors encountered in their life. This is vital to clear other secondary infections usually developed in hospitalized COVID-19 patients. SARS-CoV-2 specific memory T cells were found within all the CD45RA− subsets CD3+, CD4+, CD8+, and in the central memory and effector memory subpopulations. The procedure to obtain the cells is feasible, easy to implement for small scale manufacture, quick and cost-effective involving minimal manipulation, and without GMP condition requirements. This biobank of specific SARS-CoV-2 memory T cells would be immediately available ‘off-the-shelf’ to treat moderate/severe cases of COVID-19 increasing the therapeutic options available for these patients.


2005 ◽  
Vol 7 (6) ◽  
pp. 818-834 ◽  
Author(s):  
Yajin Ni ◽  
Susan Sun ◽  
Ibe Oparaocha ◽  
Laurent Humeau ◽  
Brian Davis ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document